JP2020523406A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523406A5 JP2020523406A5 JP2020514657A JP2020514657A JP2020523406A5 JP 2020523406 A5 JP2020523406 A5 JP 2020523406A5 JP 2020514657 A JP2020514657 A JP 2020514657A JP 2020514657 A JP2020514657 A JP 2020514657A JP 2020523406 A5 JP2020523406 A5 JP 2020523406A5
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic
- composition
- pharmaceutically acceptable
- composition according
- keratitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000007864 aqueous solution Substances 0.000 claims 5
- 239000000839 emulsion Substances 0.000 claims 5
- 206010023332 keratitis Diseases 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 239000003246 corticosteroid Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 3
- 206010013774 Dry eye Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 2
- KXDROGADUISDGY-UHFFFAOYSA-N Benzamil hydrochloride Chemical compound C=1C=CC=CC=1CN=C(N)NC(=O)C1=NC(Cl)=C(N)N=C1N KXDROGADUISDGY-UHFFFAOYSA-N 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 claims 2
- 208000029728 Eyelid disease Diseases 0.000 claims 2
- NIOHELZQFBGCEO-UHFFFAOYSA-N Phenylamil Chemical compound N=1C(Cl)=C(N)N=C(N)C=1C(=O)N=C(N)NC1=CC=CC=C1 NIOHELZQFBGCEO-UHFFFAOYSA-N 0.000 claims 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 229960002537 betamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 2
- 229960003679 brimonidine Drugs 0.000 claims 2
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 claims 2
- 229960004875 difluprednate Drugs 0.000 claims 2
- 229950009769 etabonate Drugs 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 206010034674 peritonitis Diseases 0.000 claims 2
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 claims 2
- 229960002943 prednisolone sodium phosphate Drugs 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 229960005294 triamcinolone Drugs 0.000 claims 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 2
- -1 1-benzofuran-6-ylcarbonyl Chemical group 0.000 claims 1
- 108091006146 Channels Proteins 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010059208 Eyelid pain Diseases 0.000 claims 1
- 206010016936 Folliculitis Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000023715 Ocular surface disease Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010030865 Ophthalmic herpes zoster Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010034944 Photokeratitis Diseases 0.000 claims 1
- 208000002389 Pouchitis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 229960002576 amiloride Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 201000010251 cutis laxa Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 229960001798 loteprednol Drugs 0.000 claims 1
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 claims 1
- 201000003265 lymphadenitis Diseases 0.000 claims 1
- 210000004175 meibomian gland Anatomy 0.000 claims 1
- WNBSDCKJFDZMHT-UHFFFAOYSA-N n-(diaminomethylidene)pyrazine-2-carboxamide Chemical class NC(N)=NC(=O)C1=CN=CC=N1 WNBSDCKJFDZMHT-UHFFFAOYSA-N 0.000 claims 1
- 239000007908 nanoemulsion Substances 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229960005190 phenylalanine Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229940125794 sodium channel blocker Drugs 0.000 claims 1
- 239000003195 sodium channel blocking agent Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 201000003826 superficial keratitis Diseases 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 239000004034 viscosity adjusting agent Substances 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762509015P | 2017-05-19 | 2017-05-19 | |
| US62/509,015 | 2017-05-19 | ||
| US201762591548P | 2017-11-28 | 2017-11-28 | |
| US62/591,548 | 2017-11-28 | ||
| PCT/US2018/026342 WO2018212846A1 (en) | 2017-05-19 | 2018-04-05 | Ophthalmic compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020523406A JP2020523406A (ja) | 2020-08-06 |
| JP2020523406A5 true JP2020523406A5 (https=) | 2021-05-13 |
Family
ID=64269595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514657A Pending JP2020523406A (ja) | 2017-05-19 | 2018-04-05 | 眼科用組成物および使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10555947B2 (https=) |
| EP (1) | EP3624773A4 (https=) |
| JP (1) | JP2020523406A (https=) |
| CN (1) | CN110996904A (https=) |
| WO (2) | WO2018212846A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230277557A1 (en) * | 2017-09-25 | 2023-09-07 | Surface Ophthalmics, Inc. | Pharmaceutical kits and their use for treating dry eye disease |
| WO2019060696A1 (en) | 2017-09-25 | 2019-03-28 | Surface Pharmaceuticals, Inc. | OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE |
| JP7397000B2 (ja) | 2018-04-30 | 2023-12-12 | メルク・シャープ・アンド・ドーム・エルエルシー | 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法 |
| US12144855B2 (en) | 2018-04-30 | 2024-11-19 | Merck Sharp & Dohme Llc | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| CA3124945A1 (en) * | 2018-12-27 | 2020-07-02 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| EP3705114A1 (en) * | 2019-03-06 | 2020-09-09 | Avizorex Pharma, S.L. | Ophthalmic composition for treating dry eye and symptoms thereof |
| RU2705392C1 (ru) * | 2019-07-19 | 2019-11-07 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Глазная мазь на основе 6-метил-3-(тиетан-3-ил)урацила с ранозаживляющим эффектом |
| WO2021191273A1 (en) | 2020-03-24 | 2021-09-30 | Hovione Scientia Limited | Compositions for use in treating meibomian gland dysfunction |
| KR20230110516A (ko) * | 2020-10-21 | 2023-07-24 | 아주라 오프탈믹스 엘티디 | 눈 장애의 치료를 위한 화합물 및 방법 |
| AU2022212108A1 (en) * | 2021-01-28 | 2023-08-17 | Glaukos Corporation | Formulations |
| US12310981B2 (en) | 2021-05-10 | 2025-05-27 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| US12440510B2 (en) | 2021-05-10 | 2025-10-14 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| US11672798B2 (en) * | 2021-06-03 | 2023-06-13 | Laboratorios Salvat, S.A. | Ciprofloxacin ophthalmic topical composition for treating ocular disease |
| KR102391198B1 (ko) * | 2021-08-27 | 2022-04-27 | 한림제약(주) | 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물 |
| IL313616A (en) | 2021-12-17 | 2024-08-01 | Aerie Pharmaceuticals Inc | Ophthalmic pharmaceutical compositions and uses thereof |
| US20250114375A1 (en) * | 2022-02-08 | 2025-04-10 | Orbicular Pharmaceutical Technologies Private Limited | Pharmaceutical composition of lifitegrast and loteprednol etabonate |
| WO2024028815A1 (en) * | 2022-08-04 | 2024-02-08 | Bausch + Lomb Ireland Limited | Ophthalmic composition comprising an anti-allergen and a redness reduction agent |
| CA3264067A1 (en) * | 2022-08-04 | 2024-02-08 | Bausch + Lomb Ireland Limited | OPHTHALMIC COMPOSITION COMPRISING PILOCARPINE AND A REDNESS-REDUCING AGENT |
| CN115645356A (zh) * | 2022-11-21 | 2023-01-31 | 山东诺明康药物研究院有限公司 | 一种酒石酸溴莫尼定原位凝胶及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0656779B1 (en) * | 1992-08-28 | 2000-04-12 | Pharmos Corporation | Submicron emulsions as ocular drug delivery vehicles |
| EP1143896B1 (en) * | 1998-10-20 | 2006-12-13 | The University of North Carolina at Chapel Hill | Methods of hydrating the nasal mucosal surface |
| US20050196370A1 (en) | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
| EP1622647B1 (en) * | 2003-05-12 | 2009-11-25 | Lantheus Medical Imaging, Inc. | Vitronectin receptor antagonist compounds and their use in the preparation of radiopharmaceuticals |
| US20050095205A1 (en) * | 2003-10-31 | 2005-05-05 | Ramesh Krishnamoorthy | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
| US20050182039A1 (en) * | 2004-02-13 | 2005-08-18 | Bausch & Lomb Incorporated | Use of Loteprednol etabonate for the treatment of dry eye |
| JP2007528897A (ja) | 2004-03-12 | 2007-10-18 | メルビ ホールディングス， エルエルシー | 眼表面用の潤滑剤 |
| ATE441419T1 (de) * | 2004-03-25 | 2009-09-15 | Bausch & Lomb | Verwendung von loteprednoletabonat zur behanldung von trockenen augen |
| KR20090053892A (ko) | 2006-07-25 | 2009-05-28 | 오스모티카 코프. | 점안액 |
| TWM353756U (en) * | 2008-04-24 | 2009-04-01 | zong-ren Chen | Structure of treadmill |
| US20120003296A1 (en) | 2010-07-01 | 2012-01-05 | Shantha Totada R | New methods of treating dry eye syndrome |
| HUE038366T2 (hu) | 2010-08-16 | 2018-10-29 | Allergan Inc | Módszer szabályozó T-sejtek alfa-2B adrenerg receptor agonistákkal való aktiválásához |
| US20120076738A1 (en) | 2010-09-28 | 2012-03-29 | Michael Graeber | Combination treatment for dermatological conditions |
| US20120093876A1 (en) | 2010-10-13 | 2012-04-19 | Aciex, Inc. | Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions |
| MX346312B (es) | 2011-04-05 | 2017-03-15 | Optosolve Res & Dev Ltd | Tratamientos oftalmicos. |
| EP2630952A1 (en) | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
| JP6197386B2 (ja) * | 2012-06-08 | 2017-09-20 | ライオン株式会社 | ナノエマルション粒子を含む組成物及びその製造方法 |
| KR102407735B1 (ko) * | 2014-02-14 | 2022-06-10 | 징준 후앙 | 나노에멀젼 전달 시스템의 조성물 |
| KR20170132725A (ko) * | 2015-02-24 | 2017-12-04 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 안구 건조 질환 및 다른 안과 질환을 치료하기 위한 방법 및 조성물 |
| ES2835274T3 (es) * | 2015-07-08 | 2021-06-22 | Axerovision Inc | Composiciones farmacéuticas que contienen un antagonista de la integrina alfa 4 para el tratamiento de afecciones inflamatorias oculares |
-
2018
- 2018-04-05 EP EP18801539.0A patent/EP3624773A4/en not_active Withdrawn
- 2018-04-05 JP JP2020514657A patent/JP2020523406A/ja active Pending
- 2018-04-05 WO PCT/US2018/026342 patent/WO2018212846A1/en not_active Ceased
- 2018-04-05 US US15/946,709 patent/US10555947B2/en active Active
- 2018-04-05 CN CN201880043925.0A patent/CN110996904A/zh active Pending
- 2018-04-26 WO PCT/US2018/029646 patent/WO2018212955A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523406A5 (https=) | ||
| KR102496934B1 (ko) | 안과용 제제 | |
| JP2018529693A5 (https=) | ||
| JP2008520671A (ja) | 眼科用組成物および眼の治療方法 | |
| KR100338053B1 (ko) | 안압강하용점안제 | |
| ES2911174T3 (es) | Soluciones de bimatoprost y timolol sin conservantes | |
| RU2014123472A (ru) | Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней | |
| JP2014533274A5 (https=) | ||
| CN118873533A (zh) | 眼用组合物 | |
| JP6267003B2 (ja) | ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤 | |
| CN106999452B (zh) | 前列腺素类和一氧化氮供体的组合产品 | |
| KR102115285B1 (ko) | 녹내장 치료용 점안 조성물 | |
| KR102444571B1 (ko) | 세티리진 및 토코페솔란을 포함하는 안과용 조성물 | |
| JP2011512362A (ja) | 眼科応用のためのフルオロキノロン誘導体 | |
| WO2014138018A1 (en) | Preservative free bimatoprost and timolol solutions | |
| TW201705956A (zh) | 唑系抗真菌藥之對眼瞼皮膚的投與 | |
| JP2005047909A (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
| JP2017007995A (ja) | 洗眼剤組成物及び洗眼方法 | |
| JP2016196454A (ja) | 涙腺ドラッグデリバリーシステム | |
| JP4778515B2 (ja) | 角膜疾患治療剤 | |
| JP2006306757A (ja) | 角膜疾患治療剤 | |
| JP2009517375A (ja) | 眼の疾患の治療 | |
| JPWO2022207773A5 (https=) | ||
| WO2005053672A1 (ja) | シロミラストまたはその塩を有効成分とする掻痒治療剤 | |
| HK1241269B (zh) | 前列腺素类和一氧化氮供体的组合产品 |